In SURMOUNT-5, adults with obesity and without type 2 diabetes lost an average of 20.2 percent with tirzepatide and 13.7 percent with semaglutide at 72 weeks[3]. A separate observational analysis in adults with type 2 diabetes found an uncertain difference in the combined risk of heart attack, stroke or death[2].
The monthly GLP-1 cost guide shows the range of prices across providers. In our roster, the median monthly price was$269 for injected tirzepatide and $186 for injected semaglutide. The medians cover separate groups of sellers.
On weight, a randomized trial and an indirect comparison
SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes. Each arm took its maximum tolerated weekly dose for 72 weeks. That meant tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg. Weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide [3]. Waist circumference fell 18.4 cm against 13.0 cm. The trial was open-label. It was funded by Eli Lilly, which makes tirzepatide.
A Bayesian network meta-analysis included six of 42 trials identified in its systematic review. It estimated 4.85 and 6.26 percentage points more weight loss with tirzepatide 10 mg and 15 mg, respectively, than with semaglutide 2.4 mg. The corresponding differences in waist circumference were 4.81 cm and 5.32 cm[1].
Cardiovascular outcomes in adults with type 2 diabetes
A 2026 observational analysis of five cohort studies in US insurance data emulated two cardiovascular outcome trials to validate its method, then compared the molecules directly. For the composite of myocardial infarction, stroke or death, tirzepatide against semaglutide gave a hazard ratio of 1.06 (95% CI 0.95 to 1.18) [2]. The confidence interval includes both a lower and a higher hazard with tirzepatide.
In separate cohorts, the hazard ratio for heart attack or stroke was 0.82 (95% CI 0.74 to 0.91) for semaglutide versus sitagliptin. For tirzepatide versus dulaglutide, the hazard ratio for the composite that included death was 0.87 (95% CI 0.75 to 1.01)[2].
For type 2 diabetes, the cost per patient who reaches target
A monthly price is the wrong denominator if many patients never reach their goal. One UK study took each drug’s yearly pharmacy cost and split it across only the patients who hit a combined goal [4]. Each target paired an HbA1c threshold with 5, 10 or 15 percent weight loss. Each also required no hypoglycemia. Response rates came from a post hoc analysis of SURPASS-2, which randomized 1,845 patients with type 2 diabetes taking metformin. Costs were the prices NICE appraised in TA924.
The strictest target was HbA1c at or below 6.5 percent, at least 15 percent weight loss and no hypoglycemia. Against semaglutide 1 mg, tirzepatide cost £5,650, £8,665 and £9,462 less per patient reaching it. Those figures are for 5, 10 and 15 mg over one year. The gap widened as targets got stricter. It reversed at the loosest target: HbA1c below 7.0 percent with 5 percent weight loss. There, semaglutide 1 mg cost less per patient reaching it.
The comparison of study doses explains why the semaglutide dose matters when interpreting these results. The cost-to-target breakdown sets out every threshold. For a lifetime horizon built on SURMOUNT-5, see the lifetime cost model.
What this means at the checkout
Use the billing guide to check what the quoted price includes. Then ask whether the renewal price changes with dose and confirm the supply period.
The price check helps you compare a written quote with published offers for the same medication and formulation. The tirzepatide price list shows the lowest comparable prices we track by formulation. Discuss treatment options and the study results with your prescriber.
The analysis of price differences within the same seller compares recorded offers for both drugs. Confirm that your quotes cover the same supply period and include the same fees.
Price figures are computed from this site’s own records at build time, most recently read November 2026, across 183 priced sellers. The clinical figures are cited.